North America Respiratory Diagnostics Market Size & Share Forecast 2025-2035
The North America Respiratory Diagnostics Market is poised for robust growth due to rising prevalence of chronic respiratory diseases, technological advancements in diagnostic procedures, and increased focus on early disease detection. Significant investments in research and development, increasing healthcare expenditure, and a supportive regulatory environment are further accelerating market expansion. Demand for sophisticated, rapid, and non-invasive diagnostic solutions is intensifying amongst both healthcare providers and patients, with diagnostic laboratories and hospitals forming the backbone of distribution networks across the US, Canada, and Mexico.
Latest Market Dynamics
Key Drivers
- Rising prevalence of respiratory diseases such as COPD and asthma, especially in urban populations, is escalating the demand for advanced respiratory diagnostic solutions. For instance, Abbott Laboratories expanded its point-of-care respiratory testing platforms in 2025 to meet this growing need.
- Continuous technological advancements and adoption of molecular diagnostics are improving test accuracy and speed, driving greater adoption in clinical settings. In June 2024, Thermo Fisher Scientific launched improved multiplex PCR panels tailored for respiratory pathogens.
Key Trends
- Growth in adoption of point-of-care testing (POCT) for respiratory diagnostics is accelerating market penetration, with Siemens Healthineers enhancing its decentralized testing portfolio in 2025.
- Increased integration of artificial intelligence in imaging diagnostics for respiratory conditions, as demonstrated by GE Healthcare's AI-powered lung disease detection solutions released in early 2025.
Key Opportunities
- Expansion into homecare and remote diagnostic solutions is gaining traction, with Philips rolling out connected spirometry devices for home use in 2025.
- Strategic partnerships between diagnostic service providers and digital health companies are enabling wider access to respiratory diagnostics, evidenced by Roche's collaborations with telemedicine platforms in late 2024.
Key Challenges
- Stringent regulatory requirements for respiratory diagnostic devices can delay market entry, as experienced by smaller innovative players like Bio-Rad Laboratories in 2024.
- Limited reimbursement policies for novel diagnostic tests restrict adoption in several regions, posing financial challenges for healthcare providers deploying advanced molecular diagnostics.
Key Restraints
- High cost of advanced diagnostic equipment continues to restrain adoption in resource-constrained settings, despite ongoing efforts to reduce costs by companies such as Agilent Technologies.
- Data privacy and cybersecurity concerns surrounding digital diagnostic platforms may hinder the uptake of connected respiratory diagnostic solutions, as highlighted by stakeholders in the 2025 MedTech Summit.
Market Share by Type, 2025
In 2025, molecular diagnostics tests and point-of-care tests are set to dominate the North America Respiratory Diagnostics Market by type owing to their rapid turnaround time and ability to detect multiple pathogens in a single run. Imaging tests remain crucial for comprehensive evaluation, while mechanical tests and in-vitro diagnostics continue to see use in both clinical and outpatient settings. The technological shift towards molecular and POCT reflects the growing preference for accuracy and speed in respiratory diagnostics.
Market Share by Application, 2025
Asthma and COPD account for the largest application areas in the North America Respiratory Diagnostics Market for 2025, reflecting the high incidence and need for ongoing monitoring for these conditions. Tuberculosis and lung cancer segments are also significant, highlighting the value of early and accurate diagnosis amid rising awareness and screening initiatives. Cystic fibrosis and other applications represent a smaller but growing opportunity due to advances in genetic and molecular diagnostic technologies.
Market Revenue (USD Million), 2020-2035
The North America Respiratory Diagnostics Market is expected to witness sustained revenue growth from 2020 to 2035, fueled by increasing disease burden and advancements in diagnostic technologies. Market value is projected to rise from 2,800 Million USD in 2020 to 6,850 Million USD in 2035. The highest acceleration is anticipated during 2025-2030 as molecular and point-of-care tests become mainstay options across healthcare settings.
Year-on-Year Growth (%), 2020-2035
The North America Respiratory Diagnostics Market is set to achieve a compound annual growth rate (CAGR) of 5.6% between 2025 and 2035. Year-on-year (YOY) growth is expected to peak between 2025 and 2028 due to technological rollout and increased adoption post-pandemic. Growth will moderate yet remain robust as reimbursement and regulatory frameworks stabilize.
Market by Region, 2025
The United States continues to command the lion's share of the North America Respiratory Diagnostics Market, owing to well-established healthcare infrastructure and significant investment in diagnostic research. Canada and Mexico are reporting consistent growth, driven by improved access to healthcare resources and increasing awareness around early diagnosis for respiratory ailments.
Market Share by Top Players, 2025
Major industry players maintain a competitive advantage through diversified product offerings and strong regional presence. Thermo Fisher Scientific, Abbott Laboratories, and Siemens Healthineers are the market leaders in North America, together accounting for half the market share. Smaller specialized companies and new entrants continue to make inroads via innovation and partnerships.
Market Share by Buyer Type, 2025
Hospitals and diagnostic laboratories are the predominant buyers within the North American respiratory diagnostics market, collectively making up over 60% of demand in 2025. Growing interest in homecare solutions and point-of-care testing is evident, as both providers and patients look for convenience, accessibility, and rapid results. This shift is expected to deepen as telemedicine and remote diagnostics gain further traction.
Study Coverage
| Metrics | Details |
|---|
| Years | 2020-2035 |
| Base Year | 2025 |
| Market Size | 3920 |
| Regions | United States, Canada, Mexico |
| Segments | Imaging Tests, Mechanical Tests, In-vitro Diagnostics Tests, Molecular Diagnostics Tests, Point-of-Care Tests, Others; Asthma, COPD, Tuberculosis, Lung Cancer, Other Applications |
| Players | Thermo Fisher Scientific Inc., Abbott Laboratories, Becton, Dickinson and Company (BD), F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Bio-Rad Laboratories Inc., GE Healthcare, Koninklijke Philips N.V., BioMérieux SA, Qiagen N.V., Agilent Technologies Inc., Danaher Corporation, Smiths Medical, Others |
Key Recent Developments
- June 2024: Thermo Fisher Scientific announced the launch of new multiplex PCR panels for respiratory pathogens targeting the North American market.
- July 2024: Philips introduced a connected home spirometry system enabling remote monitoring for asthma and COPD patients.
- August 2024: Siemens Healthineers released an upgraded line of point-of-care diagnostic platforms focused on rapid respiratory pathogen detection.
- September 2024: Roche entered into strategic partnerships with leading telemedicine platforms to integrate molecular respiratory diagnostic tests.
- October 2024: Abbott Laboratories received FDA approval for its latest portable respiratory virus detection system intended for outpatient clinics.
